CompletedNCT01636037
Levodopa Added to Antipsychotic Treatment for Schizophrenia
About this title
Read the official source — NCT01636037Medication studyAges 18–55Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 13
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01636037
- Official title
Show the full official title
Augmentation of Antipsychotics With L-Dopa (Sinemet)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including levodopa/carbidopa (generic version of Sinemet).
Who was this study for?
Listed age limits: 18 years to 55 years.
